Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
77°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longeveron Inc
(NQ:
LGVN
)
2.570
-0.060 (-2.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Longeveron Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial
December 20, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 20, 2023
Via
Benzinga
Smart Trackers Could Detect Aging-Related Complications in Seniors
December 12, 2023
Via
Investor Brand Network
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer’s Disease With Lomecel-B™
December 06, 2023
--News Direct--
Via
News Direct
Earnings Preview: Longeveron
November 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 05, 2023
Via
Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress.
Via
Benzinga
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Eyes ‘Encouraging’ Results from CLEAR MIND Trial
December 01, 2023
Via
Investor Brand Network
Hidden Belly Fat Could Be a Precursor of Alzheimer’s Onset Years Later
November 30, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)
November 21, 2023
Via
Investor Brand Network
Study Links Cat Parasite to Accelerated Frailty in Aging People
November 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast
November 14, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions
November 13, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update
November 10, 2023
Via
Investor Brand Network
Earnings Scheduled For November 10, 2023
November 10, 2023
Companies Reporting Before The Bell • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Sex Hormones Could Influence Alzheimer’s Development, Researchers Say
November 06, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call
November 03, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial
October 30, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
October 24, 2023
Via
Investor Brand Network
Nearly A Third Of Japan’s 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron’s (NASDAQ: LGVN) Cell Therapy Help?
October 24, 2023
--News Direct--
Via
News Direct
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
October 23, 2023
Nations all over the world are getting older, but Japan is leading the charge, with nearly a third of its total population over 65 — making Japan the oldest society in the world.
Via
Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering
October 16, 2023
Via
Investor Brand Network
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
October 13, 2023
Wa’el Hashad, CEO of Longeveron (NASDAQ: LGVN), was a guest recently on Benzinga’s All-Access.
Via
Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering
October 12, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 05, 2023
Via
Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.